Biotechnology Value Fund completed the $60m investment in Verastem.

Synopsis

Biotechnology Value Fund, a San Francisco-based private investment partnership specializing in fundamentally-driven public biotechnology investments, completed the $60m investment in Verastem, an American pharmaceutical company that develops medicines to treat certain cancers.

Principals

target

VERASTEM

bidder

Bvf Partners

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Seller Team (2)

brian stuglik

CEO at VERASTEM

Manager

target

Deal

£ 48 M

Total Value

dan calkins

CFO at VERASTEM

Manager

target

Deal

£ 48 M

Total Value

Bidder Team (2)

ryan murr

Partner at Gibson Dunn & Crutcher

Lawyer

bidder

Deals

£ 10.60 B

Total Value

mark lampert

Founder and CEO at BVF PARTNERS

Investor

bidder

Deals

£ 4.19 B

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy